A TREATMENT OPTION FOR PATIENTS WITH HER2+ METASTATIC BREAST CANCER (MBC)

Seattle Genetics cordially invites you to learn more about TUKYSA

Join us to review data from **HER2CLIMB**, a global, randomized, double-blind, controlled trial evaluating TUKYSA versus placebo, each in combination with trastuzumab + capecitabine.*[1,2]

This presentation will review key highlights about TUKYSA:

- **Study design and patient characteristics** of HER2CLIMB, which uniquely enrolled the largest cohort of patients with brain metastases (48%, n = 291/612) in a registrational trial for HER2+ MBC
- **Safety and efficacy data**, including PFS, OS, and subgroup analysis for patients with and without brain metastases
- **Mechanism of action**
- **Oral daily dosing**

Healthcare professionals, including medical oncologists, pharmacists, PAs, NPs, and RNs, are encouraged to participate in this valuable dialogue.

*HER2CLIMB included previously treated with trastuzumab, pertuzumab, and T-DM1 in the neoadjuvant, adjuvant, or metastatic setting.[1,2]

HER = human epidermal growth factor receptor; OS = overall survival; PFS = progression-free survival; T-DM1 = ado-trastuzumab emtansine.

Speaker

John Glaspy, MD, MPH

David Geffen School of Medicine at UCLA

Professor of Medicine and Associate Chief, Division of Hematology-Oncology

Date and Time

Thursday, May 20, 2021

6:00 PM Pacific

Location

Meeting Link: Join Zoom Meeting

Dial-in Number: 888 788 0099 (Toll Free)

Meeting ID: 916 4589 2573

Meeting Passcode: 247390

RSVP

To RSVP, or for information regarding TUKYSA, contact your local Seattle Genetics Account Manager.

Meg Wolf

mwolf@seagen.com

559-709-7746

Indication

TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

Important Safety Information

Warnings and Precautions

- **Diarrhea:** TUKYSA can cause severe diarrhea including dehydration, hypotension, acute kidney injury, and death. In HER2CLIMB, 81% of patients who received TUKYSA experienced diarrhea, including 12% with Grade 3 and 0.5% with Grade 4. Both patients who developed Grade 4 diarrhea subsequently died, with diarrhea as a contributor to death. Median time to onset of the first episode of diarrhea was 12 days and the median time to resolution was 8 days. Diarrhea led to TUKYSA dose reductions in 6% of patients and TUKYSA discontinuation in 1% of patients. Prophylactic use of antidiarrheal treatment was not required on HER2CLIMB.

  If diarrhea occurs, administer antidiarrheal treatment as clinically indicated. Perform diagnostic tests as clinically indicated to exclude other causes of diarrhea. Based on the severity of the diarrhea, interrupt dose, then dose reduce or permanently discontinue TUKYSA.

Please see additional Important Safety Information on following page and the accompanying full Prescribing Information.

TUKYSA® tucatinib
50 mg | 150 mg tablets

Important Safety Information (cont'd)

- **Hepatotoxicity:** TUKYSA can cause severe hepatotoxicity. In HER2CLIMB, 8% of patients who received TUKYSA had an ALT increase >5 × ULN, 6% had an AST increase >5 × ULN, and 1.5% had a bilirubin increase >3 × ULN (Grade ≥3). Hepatotoxicity led to TUKYSA dose reductions in 8% of patients and TUKYSA discontinuation in 1.5% of patients.

  Monitor ALT, AST, and bilirubin prior to starting TUKYSA, every 3 weeks during treatment, and as clinically indicated. Based on the severity of hepatoxicity, interrupt dose, then dose reduce or permanently discontinue TUKYSA.
- **Embryo-Fetal Toxicity:** TUKYSA can cause fetal harm. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential, and male patients with female partners of reproductive potential, to use effective contraception during TUKYSA treatment and for at least 1 week after the last dose.

Adverse Reactions

Serious adverse reactions occurred in 26% of patients who received TUKYSA; those occurring in ≥2% of patients were diarrhea (4%), vomiting (2.5%), nausea (2%), abdominal pain (2%), and seizure (2%). Fatal adverse reactions occurred in 2% of patients who received TUKYSA including sudden death, sepsis, dehydration, and cardiogenic shock.

Adverse reactions led to treatment discontinuation in 6% of patients who received TUKYSA; those occurring in ≥1% of patients were hepatotoxicity (1.5%) and diarrhea (1%). Adverse reactions led to dose reduction in 21% of patients who received TUKYSA; those occurring in ≥2% of patients were hepatotoxicity (8%) and diarrhea (6%).

The most common adverse reactions in patients who received TUKYSA (≥20%) were diarrhea, palmar-plantar erythrodysesthesia, nausea, fatigue, hepatotoxicity, vomiting, stomatitis, decreased appetite, abdominal pain, headache, anemia, and rash.

Lab Abnormalities

In HER2CLIMB, Grade ≥3 laboratory abnormalities reported in ≥5% of patients who received TUKYSA were decreased phosphate, increased ALT, decreased potassium, and increased AST.

The mean increase in serum creatinine was 32% within the first 21 days of treatment with TUKYSA. The serum creatinine increases persisted throughout treatment and were reversible upon treatment completion. Consider alternative markers of renal function if persistent elevations in serum creatinine are observed.

Drug Interactions

- **Strong CYP3A/Moderate CYP2C8 Inducers:** Concomitant use may decrease TUKYSA activity. Avoid concomitant use of TUKYSA.
- **Strong or Moderate CYP2C8 Inhibitors:** Concomitant use of TUKYSA with a strong CYP2C8 inhibitor may increase the risk of TUKYSA toxicity; avoid concomitant use. Increase monitoring for TUKYSA toxicity with moderate CYP2C8 inhibitors.
- **CYP3A Substrates:** Concomitant use may increase the toxicity associated with a CYP3A substrate. Avoid concomitant use of TUKYSA where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP3A substrate dosage.
- **P-gp Substrates:** Concomitant use may increase the toxicity associated with a P-gp substrate. Consider reducing the dosage of P-gp substrates where minimal concentration changes may lead to serious or life-threatening toxicity.

Use in Specific Populations

- **Lactation:** Advise women not to breastfeed while taking TUKYSA and for at least 1 week after the last dose.
- **Renal Impairment:** Use of TUKYSA in combination with capecitabine and trastuzumab is not recommended in patients with severe renal impairment (CLcr < 30 mL/min), because capecitabine is contraindicated in patients with severe renal impairment.
- **Hepatic Impairment:** Reduce the dose of TUKYSA for patients with severe (Child-Pugh C) hepatic impairment.

Please see the accompanying full Prescribing Information.

References: 1. TUKYSA [Prescribing Information]. Bothell, WA: Seattle Genetics, Inc. April 2020. **2.** Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. *N Engl J Med*. 2020;382:597-609.

SeattleGenetics®

TUKYSA® tucatinib
50 mg | 150 mg tablets

TUKYSA and its logo are registered trademarks of Seattle Genetics, Inc. Seattle Genetics and are US registered trademarks of Seattle Genetics, Inc.
© 2020 Seattle Genetics, Inc., Bothell, WA 98021 All rights reserved Printed in USA US-TUP-20-519-MT